For the first time, the FDA will consider whether to approve a trio of drugs for tiny patient populations based on trials ...

Researchers have identified six new biomarkers that could detect kidney injury faster and with more sensitivity, advancing safer drug development and improving health outcomes for patients.

Identification and qualification of pharmacogenomic biomarkers of adverse drug reaction (ADR) susceptibility will eventually permit the prediction of risk and the development of rational risk ...

Discover how precision medicine and FDA's Project Optimus are transforming clinical trials in oncology drug development.

DDR is a promising arena for the development of precision ... enables rapid configuration of biomarkers across the entire landscape of cancer drug targets, including DDR. Trained on hundreds ...

Neurological biomarkers industry is projected to witness a CAGR of 10.9% during the period 2025-2034. This growth can be ...

Now, researchers have identified six new biomarkers that could detect kidney injury faster and with more sensitivity, advancing safer drug development and improving health outcomes for patients.

Neuraly and Enigma Biomedical have signed an agreement for PMI04, a positron emission tomography (PET) imaging biomarker for ...

Genialis and Debiopharm expand collaboration to develop RNA-based predictive biomarkers for DDR therapies, advancing precision oncology.